Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

SHERWOOD MEDICAL'S FIRST INTRASCOPIC MINIMALLY INVASIVE DEVICES will be introduced at the beginning of the second quarter, the firm says March 1 in announcing its entry into the new line of business. The recently cleared line of laparoscopic irrigation and electrocautery systems was developed by Miami-based Symbiosis, which Sherwood Medical parent American Home Products purchased last September ("The Gray Sheet" Sept. 28, p. 3). The devices will be marketed by the newly developed Sherwood Intrascopic division. Sherwood Medical said in the press release that the Intrascopic division "will be responsible for the company's entry into the rapidly growing minimally invasive surgery market." Robert Egan is vice president and general manager of the new division. The unit, which will operate out of St. Louis where Sherwood is headquartered, currently has approximately 15 employees, including a sales force that exclusively will market Sherwood Intrascopic products. The firm notes that the division is not yet completely staffed. Sherwood Medical says that the development of the new division occurred independently of AHP's acquisition of Symbiosis, which also currently manufactures minimally invasive surgical instruments for Johnson & Johnson's Ethicon Endo-Surgery Division and for Boston Scientific. Sherwood Medical says that Symbiosis will continue to operate as an independent AHP subsidiary, marketing its products through Sherwood Intrascopic as well as other entities. Symbiosis is expected to be one of several sources for Intrascopic division products. Sherwood Medical notes that it continues to pursue "cost effective technologies, both internally and externally, in order to continue developing innovative products" for the Intrascopic division.

You may also be interested in...

US FDA Still Seeking Sponsor Cooperation For Oncology Label Updates

Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.

Oncology Drug Safety Is Key Focus In US FDA’s Generic Label Updates

US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.

EU GMP Annex I Proposal Would Maintain PUPSIT, Relax WFI Restrictions

The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts